Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.49 |
| ▸ | RXRB | P28702 | 1/20 | 0.49 |
| ▸ | RXRG | P48443 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 9/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL459394 | 0.87 | SLC22A12 (0.66) | SLC22A12RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL31215377 | 0.87 | SLC22A12 (0.66) | SLC22A12RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL31215352 | 0.83 | CA12 (0.59) | SLC22A12RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL457531 | 0.83 | CA12 (0.59) | SLC22A12RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL31215374 | 0.83 | MRGPRX4 (0.55) | SLC22A12RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL459191 | 0.83 | MRGPRX4 (0.55) | SLC22A12RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL31215401 | 0.83 | MRGPRX4 (0.55) | SLC22A12RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL18501241 | 0.82 | SLC22A12 (0.50) | SLC22A12RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL31215398 | 0.80 | MRGPRX4 (0.54) | SLC22A12RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL29179211 | 0.80 | MAP4K4 (0.58) | RXRARXRBRXRGMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10085957-B2 | Benzoic acid compounds for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170042844-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | PHARMA CINQ, LLC | 2017-02-16 | — | — | US | disclosed |
| US-20170042844-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | PHARMA CINQ, LLC | 2017-02-16 | — | — | US | disclosed |
| US-20170042844-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | PHARMA CINQ, LLC | 2017-02-16 | — | — | US | disclosed |
| US-20130331452-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-12-12 | — | — | US | disclosed |
| WO-2012033720-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10085957-B2 | Benzoic acid compounds for reducing uric acid | FPR1, FFAR1, GLS | SLC22A12 740/4885RXRA 439/4885RXRB 482/4885 |
| US-20130331452-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | GLS, NLRP3, XDH | SLC22A12 809/4885RXRA 978/4885RXRB 1070/4885 |
| US-20170042844-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | FPR1, FFAR1, GLS | SLC22A12 740/4885RXRA 439/4885RXRB 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.